FDA Grants QIDP Designation to Eravacycline, Tetraphase's Lead Antibiotic Product Candidate

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH ) today announced that the U.S. Food and Drug Administration (FDA) has designated the company's lead antibiotic product candidate, eravacycline, as a Qualified Infectious Disease Product (QIDP). The QIDP designation, granted for complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI) indications, will